Zhongtai: The implementation of the tenth batch of centralized procurement is expected to accelerate the clearance of generic drugs. Commercial insurance is an important incremental logic in the pharmaceutical Sector.

It is recommended to keep a close eye on the progress and implementation of commercial insurance, as improvements in the payment sector are expected to bring about a significant market trend in the Pharmaceutical Sector, with opportunities for recovery and reversal in hospital pharmaceuticals, diagnostics, and Medical Devices.

Zhitong FinanceDec 16, 2024 14:45

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): plans to use AI models to predict the interaction of biomolecules.

Gelonghui December 4th Allist Pharmaceuticals Co., Ltd. (688578.SH) stated on the interactive platform that the company's drug design team pays high attention to the application areas and development trends of AI technology, planning to use AI models to predict the interactions of biological molecules in order to guide molecular design and improve the efficiency of new drug research.

Gelonghui FinanceDec 4, 2024 17:49

shanghai allist pharmaceuticals co., ltd. (688578): Fomepizole continues to grow rapidly, reserves future pipeline for external cooperation.

Shanghai Allist Pharmaceuticals Co., Ltd. released the third quarter report for 2024, with the company achieving revenue of 2.53 billion yuan in Q1-Q3 of 2024, a year-on-year increase of +88%; net income attributable to mother was 1.06 billion yuan, a year-on-year increase of +159%; net income attributable to non-parent

china merchantsOct 27, 2024 14:51

Allist Pharmaceuticals' Q3 Profit Soars 101%, Operating Income Jumps 60%

MT NewswiresOct 25, 2024 13:12

shanghai allist pharmaceuticals co., ltd. (688578): Q3 revenue and profit both exceeded expectations, overseas clinical trials are about to make progress.

The company released its third quarter report, with Q1-3 revenue of 2.533 billion, yoy +87.97%; net profit attributable to shareholders of 1.063 billion, yoy +159%; with Q3 revenue alone at 0.957 billion, up by +59.73% year-on-year.

zhongtai SecuritiesOct 25, 2024 00:00

Shanghai Alice Pharmaceutical Technology Co., Ltd. Report for the Third Quarter of 2024

SZSIOct 25, 2024 00:00 · Announcements